Curis to Present at Upcoming 30th Annual SNO Meeting

Curis (NASDAQ: CRIS) will present clinical and preclinical data on emavusertib (CA-4948), an oral IRAK4 inhibitor, at the 30th Annual Society for Neuro‑Oncology (SNO) Meeting on November 19–23, 2025.

Rhea-AI Summary

Curis (NASDAQ: CRIS) will present clinical and preclinical data on emavusertib (CA-4948), an oral IRAK4 inhibitor, at the 30th Annual Society for Neuro‑Oncology (SNO) Meeting on November 19–23, 2025.

Key presentations: poster and rapid oral presentations on Nov 21–22, 2025 reporting emavusertib plus BTKi clinical data in Primary CNS Lymphoma (PCNSL) and Secondary CNS Lymphoma (SCNSL) by Dr. Christian Grommes, Dr. Lakshmi Nayak and Cecilia Merrigan; and an oral talk on Nov 23, 2025 by Christina von Roemeling on targeting Myddosome signaling in melanoma brain metastases. Times listed are local ET and HT for each session.

Argus Nov 14 session

+17.70% close to close 1.7x rel. volume Open Argus

Details

News Market Reaction – CRIS

On Nov 14, the day this news came out, CRIS closed 17.70% above the previous close. That session’s volume was 1.7x the stock’s average daily volume.

Data tracked by StockTitan Argus for the Nov 14 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LEXINGTON, Mass., Nov. 14, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that Curis will report emavusertib and BTKi clinical data in Primary CNS Lymphoma (PCNSL) and Secondary CNS Lymphoma (SCNSL) in three presentations and preclinical data on emavusertib in an oral presentation at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) on November 19-23:

November 21, 2025 – 4:30 PM ET (11:30 AM HT)

Format:	Poster Presentation
Presenter:	Dr. Christian Grommes, Memorial Sloan Kettering Cancer Center, NY, NY
Title:	Analysis of Genetic Mutation Profile and CNS Pharmacokinetics in Relapsed/Refractory Primary CNS Lymphoma Patients Responding to Novel Emavusertib (IRAK4i) and BTKi Combination
Format:	Poster Presentation
Presenter:	Dr. Lakshmi Nayak, Dana-Farber Cancer Institute, Boston, MA
Title:	Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Combination with Ibrutinib in Relapsed/Refractory Primary Central Nervous System Lymphoma Patients

November 22, 2025 – 4:45 PM ET (11:45 AM HT)

Format:	Rapid Oral Presentation
Presenter:	Dr. Christian Grommes, Memorial Sloan Kettering Cancer Center, NY, NY
Title:	Analysis of Genetic Mutation Profile and CNS Pharmacokinetics in Relapsed/Refractory Primary CNS Lymphoma Patients Responding to Novel Emavusertib (IRAK4i) and BTKi Combination
Format:	Poster Presentation
Presenter:	Cecilia A. Merrigan, APRN, CNP, DNP, Mayo Clinic, Rochester, MN
Title:	Promising Efficacy Signal in Secondary CNS Lymphoma Patients Treated with Emavusertib and Ibrutinib

November 23, 2025 – 3:24 PM ET (10:24 AM HT)

Format:	Oral Presentation
Presenter:	Christina von Roemeling, Ph.D., University of Florida, Gainesville, FL
Title:	Targeting Myddosome Signaling to Improve Immunotherapy in Melanoma Brain Metastases

About Curis, Inc.
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the TakeAim Leukemia Phase 1/2 study (CA-4948-102) in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS), and as a frontline combination therapy with venetoclax and azacitidine in patents with AML (CA-4948-104). Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene Discovery Technologies Limited, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge® to Genentech, a member of the Roche Group, under which they are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-present-at-upcoming-30th-annual-sno-meeting-302615742.html

SOURCE Curis, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Curis (CRIS) present emavusertib clinical data at SNO 2025?

Curis will present November 21–23, 2025 with sessions on Nov 21, Nov 22, and an oral presentation on Nov 23, 2025.

Which Curis (CRIS) presentations cover Primary CNS Lymphoma (PCNSL) data at SNO 2025?

PCNSL data are included in poster and rapid oral presentations by Dr. Christian Grommes and Dr. Lakshmi Nayak on Nov 21–22, 2025.

Who is presenting Secondary CNS Lymphoma (SCNSL) results for Curis (CRIS) at SNO 2025?

Cecilia A. Merrigan from Mayo Clinic will present promising efficacy signals in SCNSL patients treated with emavusertib and ibrutinib on Nov 22, 2025.

What preclinical topic will Curis (CRIS) cover at SNO 2025?

An oral presentation on Nov 23, 2025 by Christina von Roemeling covers targeting Myddosome signaling to improve immunotherapy in melanoma brain metastases.

What is the drug being presented by Curis (CRIS) at SNO and its mechanism?

The presentations focus on emavusertib (CA-4948), described as an orally available small-molecule IRAK4 inhibitor.